Gilead Says New Hepatitis Drug Does Not Infringe Merck IP
Gilead Sciences Inc. has asked a federal court in California to issue a declaratory judgment that its hepatitis C drug would not infringe two Merck & Co. Inc. patents, or to...To view the full article, register now.
Already a subscriber? Click here to view full article